title: HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
abstract: To determine the HIV seroprevalence in adult patients with pulmonary tuberculosis in Yaounde and to compare the incidence of adverse skin reactions in patients with and without HIV infection receiving thiacetazone-free antituberculosis treatment, we studied 235 consecutive patients aged 15 years or more admitted into the Chest Clinic of Hospital Jamot in Yaounde with a diagnosis of pulmonary tuberculosis from July 1 to December 31, 1994. HIV testing was done using two ELISAs and confirmed by Western blot. Each patient was monitored for adverse skin reactions to antituberculosis treatment during the two month initial phase of therapy in hospital. Of the 235 patients studied, 156 (66%) were males (mean age: 33 years) and 79 were females (mean age: 30.3 years). Overall, 16.6% (39 cases) of the 235 patients were HIV seropositive. The prevalence of HIV infection was significantly higher in women (24%) than in men (12.5%) (p = 0.02). Adverse skin reactions to antituberculosis treatment were observed in eleven (4.7%) of the 235 patients. The incidence of the reactions was significantly higher in HIV seropositive (23.1%) than in HIV seronegative patients (1.0%) (p < 10 - 7). Two HIV seropositive patients who developed Stevens-Johnson syndrome died. The drugs incriminated for adverse skin reactions in the nine patients who survived were pyrazinamide (four cases) and rifampicin (five cases).
authors.affiliation: Clinical Epidemiology Unit Yaounde, Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Cameroon.
authors.forename: C
authors.initials: C
authors.lastname: Kuaban
authors.forename: R
authors.initials: R
authors.lastname: Bercion
authors.forename: S
authors.initials: S
authors.lastname: Koulla-Shiro
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000009:adverse effects*; D002163:Cameroon; D003875:Drug Eruptions / Q000209:etiology*; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005260:Female; D015528:HIV Seroprevalence / Q000639:trends; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017678:Sex Distribution; D013828:Thioacetazone; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000188:drug therapy*; D014504:Urban Health
chemical_list: D000995:Antitubercular Agents; D013828:Thioacetazone